课题基金 / 基金详情

项目摘要

项目成果

KEVIN Edward HEALY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Drug development is hampered by high failure rates attributed to the reliance on non-human animal models employed during safety and efficacy testing. A fundamental problem in this inefficient process is that non- human animal models neither adequately represent human biology nor recapitulate human disease states. The discovery of patient-specific human induced pluripotent stem (hiPS) cells creates the opportunity to develop in vitro disease-specific model tissues to be used for high content drug screening and patient specific medicine. The principal milestone of this proposal is to establish integrated in vitro models of human cardiac and liver tissue based on microphysiological models of human myocardium and liver with populations of normal and patient-specific hiPS cells differentiated into cardiomyocytes or hepatocytes. We chose the heart and liver as model systems, since failure of candidate drugs is most often associated with toxicity of one of these organs. For this UH2 application we have chosen to focus on long QT syndrome as a basis for proof-of-principle of our methodology. Prolongation of the QT interval, the electrical manifestation of cardiac ventricular repolarization, is a major cause of cardiac arrhythmias and sudden death. Our model will allow for controlled fabrication of human cardiac tissue to study the function of healthy and diseased within novel microfluidic systems. We plan to integrate the diseased cardiac tissue model with a "healthy" liver model on a microfluidic platform, and then use this device as proof-of-principle system to screen drugs to "treat" the LQTS. As the heart and liver models will be integrated, we can screen for both direct and off-target toxicity of drugs on the liver. At the end of the UH2 phase, we anticipate our platform will be easily adaptable to design changes and able to integrate with other physiological systems developed by competing groups during the UH3 phase.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.biomaterials.2013.10.052
发表时间: 2014-02
期刊: BIOMATERIALS
影响因子: 14
作者: [Ma, Zhen, Koo, Sangmo, Finnegan, Micaela A., Loskill, Peter, Huebsch, Nathaniel, Marks, Natalie C., Conklin, Bruce R., Grigoropoulos, Costas P., Healy, Kevin E.]
通讯作者: Healy, Kevin E.
Physiologically relevant organs on chips.
芯片上的生理相关器官。
DOI: 10.1002/biot.201300187
发表时间: 2014-01
期刊: BIOTECHNOLOGY JOURNAL
影响因子: 4.7
作者: [Yum, Kyungsuk, Hong, Soon Gweon, Healy, Kevin E., Lee, Luke P.]
通讯作者: Lee, Luke P.
DOI: 10.1038/nprot.2018.006
发表时间: 2018-04
期刊: Nature protocols
影响因子: 14.8
作者: [Hoang P, Wang J, Conklin BR, Healy KE, Ma Z]
通讯作者: Ma Z
DOI: 10.1016/j.biomaterials.2018.11.032
发表时间: 2019-02
期刊: Biomaterials
影响因子: 14
作者: [Sylvia L Natividad-Diaz;Shane Browne;A. Jha;Zhen Ma;S. Hossainy;Yosuke K. Kurokawa;S. George;K. Healy]
通讯作者: Sylvia L Natividad-Diaz;Shane Browne;A. Jha;Zhen Ma;S. Hossainy;Yosuke K. Kurokawa;S. George;K. Healy
Microphysiological systems to interrogate the Islet-Liver-Adipose Axis in normal physiology and Type-2 Diabetes Mellitus
  • 批准号:
    10216389
  • 项目类别:
  • 资助金额:
    $230.55万
  • 财政年份:
    2018
  • 负责人:
    KEVIN Edward HEALY
  • 依托单位:
Microphysiological systems to interrogate the Islet-Liver-Adipose Axis in normal physiology and Type-2 Diabetes Mellitus
  • 批准号:
    10462610
  • 项目类别:
  • 资助金额:
    $228.78万
  • 财政年份:
    2018
  • 负责人:
    KEVIN Edward HEALY
  • 依托单位:
Microphysiological systems to interrogate the Islet-Liver-Adipose Axis in normal physiology and Type-2 Diabetes Mellitus
  • 批准号:
    10224184
  • 项目类别:
  • 资助金额:
    $229.45万
  • 财政年份:
    2018
  • 负责人:
    KEVIN Edward HEALY
  • 依托单位:
Human heart-on-a-chip for screening cardiomyopathy and chemotherapeutic cardiotoxicity
  • 批准号:
    9240184
  • 项目类别:
  • 资助金额:
    $59.23万
  • 财政年份:
    2017
  • 负责人:
    KEVIN Edward HEALY
  • 依托单位:
海外基金